What is Gaucher disease?

Gaucher Disease: Overview

Gaucher disease is the most common lysosomal storage disorder, caused by deficiency of the enzyme acid β-glucosidase (glucocerebrosidase), leading to accumulation of glucosylceramide in macrophages throughout the body. 1, 2

Genetic Basis and Epidemiology

Gaucher disease is an autosomal recessive disorder caused by pathogenic variants in the GBA1 gene located on chromosome 1q21. 1, 3

Prevalence varies significantly by population:

• General population: 1 in 40,000 to 1 in 60,000 births 1
• Ashkenazi Jewish population: approximately 1 in 450 to 1 in 800 births 1, 2
• The disease is pan-ethnic and occurs worldwide 1

Over 400 pathogenic variants have been identified in GBA1, many resulting from recombination events between the gene and a highly homologous pseudogene. 3

Disease Classification and Clinical Phenotypes

Gaucher disease exists on a continuous clinical spectrum but is traditionally subdivided into three main types based on neurological involvement and age of onset 1:

Type 1 (Non-neuronopathic) - 95% of cases in Europe/USA

Key features:

• Childhood to adult onset (though can present at any age)
• No primary CNS involvement (exception: increased risk of Parkinson disease)
• Visceral manifestations dominate the clinical picture

Clinical manifestations include:

• Hepatomegaly (80% of patients) and splenomegaly (90% of patients) 1
• Hematologic abnormalities: anemia, thrombocytopenia, leukopenia
• Bone disease: pain crises, osteopenia, aseptic necrosis of femoral head, lytic lesions, pathological fractures
• Growth retardation and delayed puberty (when presenting in childhood)
• Pulmonary involvement: interstitial lung disease, pulmonary hypertension
• Increased risk of multiple myeloma and Parkinson disease 1, 2

Important clinical pearl: Type 1 patients presenting in childhood typically have more severe visceral and bone manifestations than those presenting in adulthood. 1

Type 2 (Acute Neuronopathic) - 1% of cases

Characteristics:

• Neonatal to infantile onset
• Rapidly progressive, fatal course
• Death typically occurs within the first 2 years of life 1

Clinical features:

• Severe neurological involvement: bulbar palsies, hypertonicity, abnormal ocular saccades, cognitive impairment
• Hepatosplenomegaly, anemia, thrombocytopenia
• Hydrops fetalis (in neonatal presentation)
• Interstitial lung disease
• Arthrogryposis in severe cases 1

Type 3 (Subacute/Chronic Neuronopathic) - 4-5% of cases

Characteristics:

• Infantile to childhood onset
• Subacute, slowly progressive course
• Variable neurological and visceral involvement

Clinical manifestations:

• Neurological: oculomotor apraxia, myoclonic epilepsy, generalized tonic-clonic seizures, cognitive impairment
• Visceral: hepatosplenomegaly, interstitial lung disease
• Hematologic: anemia, thrombocytopenia
• Bone disease similar to Type 1 1

Type 3 subtypes have been proposed:

• Type 3a: Rapidly progressive neurological manifestations with variable visceral symptoms
• Type 3b: More pronounced visceral/bone symptoms with less severe, slowly progressive CNS involvement
• Type 3c: Primarily in Druze descent patients; mild visceral disease, slowly progressive neurological manifestations, unique cardiac valvular calcifications and corneal opacities 1

Pathophysiology

The enzymatic deficiency of acid β-glucosidase (glucocerebrosidase) prevents degradation of glucosylceramide, leading to its accumulation in lysosomes of macrophages. 1, 2

These lipid-laden macrophages (Gaucher cells) infiltrate:

• Bone marrow (causing cytopenia and bone lesions)
• Spleen (causing splenomegaly)
• Liver (causing hepatomegaly)
• Other organs including lungs, lymph nodes, and in neuronopathic forms, the central nervous system 1, 4

The accumulation of glucosylsphingosine (lyso-Gb1), the deacylated derivative of glucosylceramide, serves as a specific biomarker for disease activity and monitoring. 2, 3

Diagnosis

Diagnosis is confirmed by demonstrating deficient acid β-glucosidase enzyme activity in peripheral blood leukocytes or dried blood spots. 1, 3

Genetic testing should identify pathogenic variants in GBA1 for:

• Confirmation of diagnosis
• Prognostic value (genotype-phenotype correlations)
• Family screening and genetic counseling 1, 3

Key genotype-phenotype correlations: 1

• p.N370S/any variant → Type 1 GD
• p.L444P/p.L444P → Type 3a or 3b GD
• p.D409H/p.D409H → Type 3c GD
• p.L444P/recombinant or recombinant/recombinant → Type 2 GD

Biomarkers for monitoring include:

• Lyso-Gb1 (most specific, directly reflects disease activity)
• Chitotriosidase activity
• Tartrate-resistant acid phosphatase
• Angiotensin converting enzyme
• CCL18/PARC 2

Treatment Options

For Type 1 and Type 3 Gaucher Disease

Enzyme Replacement Therapy (ERT) - First-line treatment: 1, 2

Three FDA-approved recombinant enzymes are available:

• Imiglucerase (Cerezyme)
• Velaglucerase alfa (VPRIV)
• Taliglucerase alfa (UPLYSO)

ERT effectively addresses:

• Hepatosplenomegaly (improvement within first year)
• Anemia and thrombocytopenia (improvement within first year)
• Bone disease (response slower, may take several years) 1

Important caveat: ERT does not cross the blood-brain barrier effectively, so neurological manifestations in Type 3 are not reliably improved. 1

Substrate Reduction Therapy (SRT): 1, 2

Two oral agents are available:

• Miglustat (Zavesca): Second-line therapy for adult Type 1 patients with mild-to-moderate disease who cannot receive ERT or refuse it. Less effective than standard-dose ERT. Common adverse effects include diarrhea (85-90%), weight loss, peripheral neuropathy, tremor.

• Eliglustat: FDA-approved as first-line treatment for Type 1 GD patients of any severity. Requires CYP2D6 metabolic phenotyping before initiation. Contraindicated in pregnancy. Demonstrates similar efficacy to ERT with improved quality of life. 5

For Type 2 Gaucher Disease

No disease-specific therapy is available. Only supportive care is recommended due to the rapid, fatal progression. 1

Treatment Initiation Criteria

For Type 1 GD: Treatment should begin if two or more of the following manifestations are present: 1

• Significant hepatosplenomegaly
• Thrombocytopenia or anemia
• Bone disease manifestations

For Type 3 GD: Patients should be started on treatment immediately upon diagnosis. 1

Monitoring and Follow-up

Symptomatic children should be monitored every 6 months with: 6

• Physical examination including growth assessment
• Spleen and liver volume measurement
• Neurologic examination
• Hematologic indices

Annual to biannual skeletal assessments including:

• Bone density measurements
• Imaging (preferably MRI) of lumbar vertebrae and lower limbs 6

Pre-symptomatic children (detected through family screening) require annual examinations including bone density, with treatment initiated only if signs/symptoms develop. 6

Important Clinical Considerations

Diagnostic delay remains a significant problem leading to accumulation of irreversible complications, particularly bone disease. High index of suspicion is essential for timely diagnosis. 7

Pregnancy considerations: Only ERT can be used during pregnancy; eliglustat should be avoided. 5

Long-term risks in Type 1 GD: Increased risk of Parkinson disease and possibly multiple myeloma, even in treated patients. 1, 2

Genetic counseling is essential for affected families, particularly in high-prevalence populations, to discuss recurrence risk and options for prenatal diagnosis. 6, 7